CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
IPO Year:
Exchange: AMEX
Website: cormedix.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/7/2025 | $18.00 | Outperform | Leerink Partners |
| 1/13/2025 | $15.00 | Buy | D. Boral Capital |
| 8/26/2024 | $13.00 | Buy | Rodman & Renshaw |
| 8/10/2023 | $6.00 | Outperform | RBC Capital Mkts |
For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation
Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination
Leerink Partners initiated coverage of Cormedix with a rating of Outperform and set a new price target of $18.00
D. Boral Capital initiated coverage of Cormedix with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Cormedix with a rating of Buy and set a new price target of $13.00
RBC Capital Mkts initiated coverage of Cormedix with a rating of Outperform and set a new price target of $6.00
Needham reiterated coverage of Cormedix with a rating of Buy and set a new price target of $29.00 from $31.00 previously
Needham initiated coverage of Cormedix with a rating of Buy and set a new price target of $31.00
Truist Securities reiterated coverage of Cormedix with a rating of Buy and set a new price target of $35.00 from $20.00 previously
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
SC 13G/A - CorMedix Inc. (0001410098) (Subject)
SC 13G/A - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
SC 13G/A - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
SC 13D/A - CorMedix Inc. (0001410098) (Subject)
10-Q - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
DEFA14A - CorMedix Inc. (0001410098) (Filer)
DEF 14A - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
10-K - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, May 6th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Conference ID:10198548Webcast:Webcast Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic pr
‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its second full quarter of DefenCath sales since commencing outpatient launch in
BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25th @ 8:30am ETDomestic: 1-844-481-2557International: 1-412-317-0561Conference ID: 10197392Webcast: Webcast Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and comme
‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter and nine months ended September 30, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its first full quarter of DefenCath sales since commencing outpatient launch in July 2024. The Com
BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2024, before the market opens on Wednesday, October 30, 2024, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, October 30th @ 8:30am EDTDomestic:1-844-481-2557International:1-412-317-0561Webcast:Webcast Link About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for
BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the second quarter and six months ended June 30, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports our initial partial quarter of sales since DefenCath's inpatient launch on April 15th. The Company reported net sales of $0.8 million for the second quarter, which primarily represents trade stocking for inpatient facilities. The company has started to see pull-through of units to inpati
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 14, 2024, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, August 14th @ 8:30am ET Domestic:1-877-270-2148International:1-412-902-6510Webcast:Webcast Link About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the pr
BERKELEY HEIGHTS, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024 and provided an update on its business. Recent Corporate Highlights: On April 2, 2024, CMS published its HCPCS coding decision for DefenCath, establishing a new HCPCS Level II code for the product. CMS subsequently notified the Company on April 18th of its determination that DefenCath meets the criteria for a Transitional Drug Add-On Payment (TDAPA) and will be effective July 1, 2024. The TDAP
BERKELEY HEIGHTS, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2024, before the market opens on Thursday, May 9, 2024, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, May 9th @ 8:30am ETDomestic:1-888-886-7786International:1-416-764-8658Conference ID:32817785Webcast:Webcast Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic produc
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, May 6th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Conference ID:10198548Webcast:Webcast Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic pr
‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited first quarter results and provides an update on its business. These include the following key updates: CorMedix announces preliminary, unaudited net revenue of $39.0 million for 1Q 2025, and expects 1Q 2025 adjusted EBITDA(1) to exceed $22
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on April 7-10, 2025. 24th Annual Needham Virtual Healthcare Conference Date:Tuesday, April 8, 2025Time:2:15p.m. EDTFormat:Fireside ChatWebcast:Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threa
‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its second full quarter of DefenCath sales since commencing outpatient launch in
BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25th @ 8:30am ETDomestic: 1-844-481-2557International: 1-412-317-0561Conference ID: 10197392Webcast: Webcast Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and comme
BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities. This collaboration aims to enhance access to critical therapies for the estimated 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs. This engagement leverages WSI PBG's proven expertis
‒ Q4 2024 Unaudited Net Revenue of Approximately $31mm ‒ ‒ FY 2024 Unaudited Net Revenue of Approximately $43mm ‒ ‒ Expects Q4 Adjusted EBITDA to Exceed $12mm ‒ BERKELEY HEIGHTS, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited fourth quarter results and provides an update on its business. These include the following key updates: CorMedix announces preliminary, unaudited net revenue of approximately $31mm for Q4 2024 and approximately $43mm for FY 2024, and expects Q4 2024 adjusted EBITDA(1
BERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced it will be added to the Nasdaq Biotechnology Index (NASDAQ:NBI) (the "NBI"). CorMedix's addition to the NBI will become effective prior to the market open on Monday, December 23, 2024. The NBI is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical companies and is a modified market capitalization weighted index. The NBI is reconstituted annual
BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today highlights key policy changes from CMS that benefit hemodialysis patients. Yesterday, the Centers for Medicare & Medicaid Services (CMS) and the Center for Medicare and Medicaid Innovation (CMMI) released important policy updates that will broaden the access of Medicare patients managing End Stage Renal Disease (ESRD) and on dialysis to innovative new therapies. Beginning in January 2025, CMMI's Kidney Care Choices (KCC) value-based care model will carve out Tr
BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no longer serve as the Company's General Counsel, effective December 12, 2023, and will be separating from CorMedix effective December 31, 2023, to pursue other opportunities. Ms. Zelnick Kaufman has
– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix Inc. will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the crea
BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors. Following the appointment of Mr. Stewart, the Board will comprise 8 directors, 7 of which are independent. "We are pleased to welcome Rob Stewart to the CorMedix Board," said Joseph Todisco, Chief Executive Officer of CorMedix. "Rob's deep experience in global pharmaceutical management and broad professional network in the pharma space will be inval
BERKELEY HEIGHTS, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Joseph Todisco as Chief Executive Officer of the company. Mr. Todisco also will join the CorMedix Board of Directors. The company expects Mr. Todisco to join CorMedix on May 16th or such earlier date as he completes his contractual responsibilities to his current employer. Myron Kaplan, Chairman of CorMedix's Board of Directors commented, "We are delighted to welcome Joe to CorMedix as the new Chief Executi
BERKELEY HEIGHTS, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent business events. Recent Business Highlights: CorMedix announced the appointment of Tom Nusbickel as the Company's Executive Vice President and Chief Commercial Officer.CorMedix successfully completed the agreed upon protocol for the manual extraction study identified in the Complete Response Letter that FDA is requiring as confirmatio